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Sir,
Frovatriptan versus other treatments for acute
migraine
There are now three crossover, double-blind, randomized
controlled trials (RCTs) of similar design comparing
frovatriptan 2.5 mg with zolmitriptan 2.5 mg [1], rizatrip-
tan 10 mg [2] and almotriptan 12.5 mg [3]. Each RCT
found no signiﬁcant differences between the treatments
with regard to patients’ expressed preferences and, as
secondary outcome measures, the conventional end-points
of pain-freedom and headache relief [4]. A meta-analysis
of the three trials, all without placebo comparison, found
them to be the sufﬁcient evidence of equal efﬁcacy of
frovatriptan and these other triptans [5].
Is this useful knowledge? There appears to be a con-
sensus supporting head-to-head comparisons between
triptans as the evidential basis for selecting best treatment.
Clinical experience, which is not easily converted into
formal evidence, nonetheless demonstrates that differences
between triptans at group level are generally less inﬂuential
than the differences in individual responses to them. So, in
practice, those for whom triptans are indicated will still
need to make their own comparative assessments.
The prior question is: for whom are triptans indicated?
Accordingly, one important comparative RCT is missing.
Effervescent aspirin 1,000 mg was quite similar to suma-
triptan 50 mg in the treatment of migraine attacks in a
meta-analysis of three RCTs [6]. The World Health
Organization currently advocates only aspirin or paraceta-
mol as treatments for acute migraine in adults [7]. It would
be of great help to people with migraine worldwide if
triptans were shown to be superior to aspirin.
The clinically relevant RCT is therefore frovatriptan
2.5 mg versus effervescent aspirin 1,000 mg with the
crossover design and, ideally, placebo control [4].
Yours sincerely
Peer Tfelt-Hansen, MD, DMSc
Timothy J Steiner, MB, PhD, LLM
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